STOCK TITAN

Bicycle Therapeutics Plc - BCYC STOCK NEWS

Welcome to our dedicated news page for Bicycle Therapeutics Plc (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bicycle Therapeutics Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bicycle Therapeutics Plc's position in the market.

Rhea-AI Summary
Bicycle Therapeutics (NASDAQ: BCYC) announces the acceptance of two abstracts for poster presentation at the 2024 ASCO Annual Meeting. The abstracts focus on the evaluation of clinical pharmacokinetics and safety of Bicycle Toxin Conjugates, as well as a phase 2/3 study targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Bicycle Therapeutics plc (BCYC) will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024. The chat will be live-streamed on the company's website, with a replay available afterward.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
conferences
-
Rhea-AI Summary
Bicycle Therapeutics plc (NASDAQ: BCYC) announces the acceptance of three abstracts for poster presentation at the AACR Annual Meeting 2024. The presentations focus on novel therapies for solid tumors and immune modulation for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics plc (BCYC) will be participating in key investor conferences in March 2024 to discuss its innovative therapeutics based on bicyclic peptide technology. The company will engage in fireside chats at TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
conferences
-
Rhea-AI Summary
Bicycle Therapeutics plc (NASDAQ: BCYC) reported strong financial results for Q4 and full year 2023. The company highlighted progress in its oncology portfolios and discovery pipeline, with promising clinical data for BT8009 in metastatic urothelial cancer. Recent events include the appointment of Stephen Sands to the Board of Directors and a cash position of $526.4 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
-
Rhea-AI Summary
Bicycle Therapeutics plc (NASDAQ:BCYC) will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 14, 2024. The company's management will discuss its proprietary bicyclic peptide technology. A live webcast and replay of the event will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
Rhea-AI Summary
Bicycle Therapeutics (Nasdaq: BCYC) is hosting an R&D Day to provide clinical updates for BT8009, BT7480, and BT5528, showcasing the potential of its Nobel Prize-winning science and strategy to develop therapies for Nectin-4-driven cancers and historically undruggable targets. The company aims to address a wide range of diseases through its novel Bicycle® platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.93%
Tags
none
-
Rhea-AI Summary
Bicycle Therapeutics plc (NASDAQ:BCYC) will host its first Research and Development (R&D) Day on December 14. The event will feature an overview of the company’s R&D strategy, pipeline opportunities, and clinical updates for BT8009, BT5528, and BT7480. Executives will also highlight the capabilities of its Bicycle® platform technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.51%
Tags
conferences
-
Rhea-AI Summary
Bicycle Therapeutics reported financial results for Q3 2023 and provided corporate updates. They aligned with the FDA on an expedited clinical development plan for BT8009 in metastatic bladder cancer. BT8009 was selected for the FDA's CMC Development and Readiness Pilot Program. They have cash and cash equivalents of $572.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.87%
Tags
Rhea-AI Summary
Bicycle Therapeutics (NASDAQ:BCYC) will participate in investor conferences in November, including TD Cowen 7th Annual Fall Oncology Innovation Summit on November 3rd and Jefferies London Healthcare Conference on November 15th. Live webcasts of the fireside chats will be accessible on Bicycle's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
conferences
Bicycle Therapeutics Plc

Nasdaq:BCYC

BCYC Rankings

BCYC Stock Data

832.62M
6.17%
91.75%
6.71%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United Kingdom
Cambridge

About BCYC

bicycle therapeutics is a biotechnology company with big ambitions. we aim to revolutionise the pharmaceutical landscape with our disruptive technology and proprietary bicyclic peptide (bicycle®) product platform and to develop transformational new therapies for patients to improve future treatment options in oncology. bicycles, a new class of small molecular weight drug conjugates for oncology and other diseases, are designed to have superior targeting abilities and to be more efficacious and better tolerated than existing drug conjugate modalities. they combine the properties of several therapeutic entities in a single modality, exhibiting the affinity and selective pharmacology associated with antibodies; the distribution kinetics of small molecules, allowing rapid tumor penetration; and the “tuneable” pharmacokinetic half-life and renal clearance of peptides, sparing cytotoxin-payload derived liver and gastrointestinal toxicity. our unique ip is based on the work of scientific foun